Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Safety outcomes of darolutamide vs apalutamide and enzalutamide in nmCRPC

Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) using matching-adjusted indirect comparisons. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.